Page last updated: 2024-08-20

dextrothyroxine and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

dextrothyroxine has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hu, J; Wan, H; Wang, J; Xu, Y	1

Other Studies

1 other study(ies) available for dextrothyroxine and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Article	Year
Antibiotic ivermectin selectively induces apoptosis in chronic myeloid leukemia through inducing mitochondrial dysfunction and oxidative stress. Biochemical and biophysical research communications, 2018, 02-26, Volume: 497, Issue:1 Topics: Animals; Anthelmintics; Anti-Bacterial Agents; Apoptosis; Dose-Response Relationship, Drug; Humans; Ivermectin; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, SCID; Mitochondria; Oxidative Stress; Treatment Outcome	2018

Article

Year

Antibiotic ivermectin selectively induces apoptosis in chronic myeloid leukemia through inducing mitochondrial dysfunction and oxidative stress.

Biochemical and biophysical research communications, 2018, 02-26, Volume: 497, Issue:1

Topics: Animals; Anthelmintics; Anti-Bacterial Agents; Apoptosis; Dose-Response Relationship, Drug; Humans; Ivermectin; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, SCID; Mitochondria; Oxidative Stress; Treatment Outcome

2018